Cancer

FDA approves pembrolizumab plus axitinib for advanced RCC

(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday.

Medical research

Cardiac dysfunction in Duchenne's

Duchenne muscular dystrophy (DMD) is a severe muscle disease that causes progressive muscle weakening and degeneration.

page 1 from 23